Krokos Bio

Krokos Bio is a biotechnology company focused on developing next-generation biologics for the treatment of central nervous system (CNS) disorders. The company leverages a proprietary platform designed to efficiently transport therapeutic molecules across the blood-brain barrier (BBB), which has historically been a significant obstacle in neuro-drug development. Founded by former Regeneron executives Christos Kyratsous and Aris Economides, Krokos Bio aims to address high unmet needs in neurodegenerative diseases such as Alzheimer's and Parkinson's. Their approach involves engineering antibodies and proteins with specialized shuttle mechanisms to ensure high brain penetration and therapeutic efficacy. The company is currently in the pre-clinical stage, advancing a pipeline of candidates targeting various neurological pathways.